Clinical Trial

Caspofungin for Pneumocystis Pneumonia in PLWHIV.

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 19, 2024 (before its estimated January 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Pneumocystis jirovecii pneumonia is a significant concern in peaple with HIV/AIDS, often severe and potentially fatal. While trimethoprim/sulfamethoxazole remains the primary treatment, safety concerns exist with alternative options. Research on Pneumocystis jirovecii's beta-D glucan composition has prompted investigations into echinocandins like caspofungin, showing promise in murine models and some positive results in human studies. Evaluating caspofungin's efficacy through observational studies is crucial due to safety advantages over current treatments and limited documented data.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-11-13.
Trial Details
NCT Number NCT06691321
Lead Sponsor Instituto Nacional de Enfermedades Respiratorias
Conditions HIV-1-infection, Pneumocystis Pneumonia
Enrollment 60 participants
Start Date 2023-08-01
Primary Completion 2025-01-01 (estimated)
Study Completion 2025-09-01 (estimated)
Updated on ClinicalTrials.gov 2024-11-19